3QBD

Company Overview

Snapshot

Founded in January 2000, 3QBD operates with 1–10 employees. The company holds a patent for its diagnostic technology. 3QBD ceased to operate in December 2020.

Business overview

3QBD develops a patented VG-Test device utilizing ion mobility spectrometry technology to diagnose bacterial vaginosis within 60 seconds. This rapid diagnostic tool is designed to provide immediate and accurate detection of infections such as vaginosis, candidiasis, and trichomoniasis from a vaginal fluid swab. The company aims to expand its research into other medical fields, particularly oncology, to detect additional infections and diseases. 3QBD operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices, serving healthcare providers.

Company Intelligence Q&A

What is 3QBD's primary product?

3QBD's primary product is the VG-Test device, which uses ion mobility spectrometry technology for rapid bacterial diagnostic testing.

What types of infections can the VG-Test device detect?

The VG-Test device can detect infections such as vaginosis, candidiasis, and trichomoniasis within one minute.

What is the core technology behind 3QBD's diagnostic device?

The core technology behind 3QBD's diagnostic device is patented ion mobility spectrometry.

What are 3QBD's future research expansion plans?

3QBD plans to expand its research into other medical fields to detect additional infections and diseases, particularly in the area of oncology.

When did 3QBD cease operations?

3QBD ceased to operate in December 2020.